FDA and Novo Nordisk Alert Consumers to Counterfeit Ozempic
By Stephanie Brown HealthDay Reporter
MONDAY, April 21, 2025 -- The U.S. Food and Drug Administration and the pharmaceutical company Novo Nordisk are urging consumers to be on the lookout for counterfeit Ozempic (semaglutide) and to refrain from using the imitation drugs.
Several hundred units of Ozempic injection 1 mg have found their way into the drug supply chain in the United States. The seized counterfeit products display a combination of lot number PAR0362 (an authentic lot number) and illegitimate serial numbers that begin with the following eight digits: 51746517. Only products with this lot number coupled with the erroneous serial number are considered counterfeit products.
The FDA and Novo Nordisk are currently testing the seized products but do not yet have any information regarding the identity, quality, or safety of these drugs. The FDA investigation is ongoing.
Six adverse event reports have been received by the FDA related to this particular lot of Ozempic. However, these reports, all submitted by Novo Nordisk, do not appear to be connected to the counterfeit product.
Pharmacies and patients are urged to double-check their Ozempic box to see if it features the combination of lot number and incorrect serial number. If so, these products are considered counterfeit and should not be used.
Suspicious Ozempic products should be reported to Novo Nordisk or directly to the FDA. In addition, any adverse effects from the use of Ozempic should be reported to the FDA MedWatch Safety Information and Adverse Event Reporting Program and to Novo Nordisk (1-800-727-6500).
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted April 2025
Read this next
First Weight-Loss Pill From Lilly, Orforglipron, Shows Promising Results
FRIDAY, April 18, 2025 — A new pill designed to help with weight loss and blood sugar control is showing promise in early studies. Eli Lilly said its experimental drug...
Pregnancy Complications Affect Future Heart Health
FRIDAY, April 18, 2025 -- Complications during pregnancy can mean a woman’s future heart health is at risk, particularly if she is overweight or obese, a new study...
Pfizer Ends Testing of Obesity Pill, Danuglipron, After Possible Liver Injury
TUESDAY, April 15, 2025 — Pfizer has stopped developing a once-daily pill to treat obesity after a person in a clinical trial showed signs of a possible liver injury. The...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.